Stock Financial Ratios, Dividends, Split History

SEMG / Semgroup Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,683.60
Enterprise Value ($M)4,443.00
Book Value ($M)1,620.16
Book Value / Share20.50
Price / Book1.02
NCAV ($M)292.87
NCAV / Share3.71
Price / NCAV6.72
Share Statistics
Common Shares Outstanding 78,672,995
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Weighted Average Number Of Diluted Shares Outstanding 71,418,000
Weighted Average Number Of Shares Outstanding Basic 71,418,000
Common Shares Outstanding2 0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.00
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.01
Balance Sheet (mrq) ($M)
Quick Ratio1.34
Current Ratio1.46
Income Statement (mra) ($M)
Sales Revenue Services Net391,266,000.00
Sales Revenue Net2,081,917,000.00
Sales Revenue Goods Net1,621,918,000.00
Other Sales Revenue Net62,890,000.00
Operating Income97.47
Net Income-17.15
Earnings Per Share Basic-0.24
Earnings Per Share Diluted-0.24
Cash Flow Statement (mra) ($M)
Cash From Operations140.48
Cash from Investing-439.80
Cash from Financing-439.80
Identifiers and Descriptors
Central Index Key (CIK)1489136
Related CUSIPS
081663A10 81663A905 81663A113 81663A955 081663N20

Split History

Stock splits are used by Semgroup Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Top Analyst Upgrades and Downgrades: Barrick Gold, Buckeye Partners, Interdigital, Penn Virginia, SeaWorld, Weight Watchers and More

2018-06-12 247wallst
Futures are trading somewhat higher this morning, perhaps marking the apparent initial success of the summit that was held in Singapore between President Donald Trump and North Korean leader Kim Jong Un. Diplomacy aside, most of Wall Street is focused on the Federal Reserve meeting this week, and the potential for another increase in the federal funds rate. (129-2)

Top Analyst Upgrades and Downgrades: Altria, ConocoPhillips, First Data, Match Group, NXP Semiconductor, Seattle Genetics and More

2018-06-11 247wallst
The futures are trading slightly higher Monday morning as investors are hoping for another solid week like the one the markets produced last week, when both the NASDAQ and the Russell 2000 hit new all-time highs. With the second quarter starting to wind down, some of the companies that will be reporting in July could start releasing earnings warnings, so it pays to stay alert now. (110-2)

MLPs: Differentiated Performance

2018-06-03 seekingalpha
Midstream and MLPs synched up this week to rally 2.7%, outperforming the S&P 500 and utilities, despite renewed oil price angst this week. Midstream stocks and MLPs resumed their recovery after last week's pause, and have now posted gains in 7 of the last 10 weeks. After bottoming in late March, the AMZ and AMEI have posted total returns of 16.2% and 12.3%, respectively. The rally has helped the MLP Index break back into positive territory year-to-date, and the MLP Index closed the week almost exactly at its 200-day moving average (269. (62-0)

Should WisdomTree U.S. SmallCap Dividend Fund (DES) Be on Your Investing Radar?

2018-05-30 zacks
Launched on 06/16/2006, the WisdomTree U.S. SmallCap Dividend Fund (DES - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Value segment of the US equity market. (8-1)

SemGroup, DCP Midstream Commence Open Season for NGL Pipeline

2018-05-29 zacks
SemGroup Corporation (SEMG - Free Report) recently announced a binding open season along with DCP Midstream, LP (DCP - Free Report) for the White Cliffs Pipeline and Southern Hills Pipeline, which will provide natural gas liquids (NGL) shipping services. The project is expected to connect Weld County, CO and Mont Belvieu, TX. (1-0)

CUSIP: 81663A105